BPGbio
Boston, Massachusetts, United States · Artificial Intelligence, Biotechnology, Health Care
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advance
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 73
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- bpgbio.com
- Company page
Recent activity at BPGbio
- : BPGbio Appoints Chas Bountra as Executive Vice President and Chief Science Officer
- : BPGbio Appoints Brian Berman as Interim Chief Medical Officer
- : BPGbio, Inc. Presents Findings on Pancreatic Cancer Patient Subtypes at ASCO GI 2025 to Improve Treatment Strategies.
- : BPGbio Announces Participation in US Pharma Partnering Summit to Present on E2-based Therapeutics for Targeted Protein Degradation.
- : BPGbio Appoints Ritesh Srivastava as General Counsel
Leadership
- Chas Bountra, Chief Science Officer
- Brian Berman, Chief Medical Officer
- Ritesh Srivastava, General Counsel
Verified email and direct lines for BPGbio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
BPGbio in the news
- BPGbio Presents Phase 2 Glioblastoma Data Update at ESMO - GlobeNewswire (Oct 26, 2026)
- BPGbio Reports Encouraging Preliminary Data from Ongoing Phase 2 Study of BPM31510 in Newly Diagnosed Glioblastoma - BioSpace (Jul 15, 2026)
- BPGbio Publishes Pioneering Research on Novel Brain-Penetrant Therapeutic Candidate for Glioma - GlobeNewswire (Oct 28, 2026)
- BPGbio Wins 2025 AI Drug Development Innovation Award from Biotech Breakthrough Awards - Yahoo Finance (Nov 06, 2025)
- BPGbio Appoints Former Oxford Pro-Vice Chancellor for Innovation Chas Bountra, Ph.D., as Executive Vice President and Chief Scientific Officer - BioSpace (Apr 21, 2026)
- BPGbio moves closer to Phase 3 in rare mitochondrial disease - Longevity.Technology (Jul 03, 2026)
- BPGbio Appoints Jason Krause as Senior Vice President and General Counsel - GlobeNewswire (Oct 22, 2026)
- UPDATE - BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency - BioSpace (Jan 22, 2026)
Companies similar to BPGbio
- Newronika · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Graph Therapeutics · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Shift Bioscience · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Pathos AI · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
- Change Agents Corporation. · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Therapeutics
About BPGbio: questions and answers
What does BPGbio do?
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advance
Where is BPGbio headquartered?
BPGbio is headquartered in Boston, Massachusetts, United States.
How many employees does BPGbio have?
BPGbio has about 73 employees.
What is the latest news on BPGbio?
On Apr 21, 2026, BPGbio Appoints Chas Bountra as Executive Vice President and Chief Science Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy